- Details
- Daniel Spratt and Todd Morgan discuss the analysis of why is it that black men appear to be dying more often of prostate cancer. They review their approach to understanding more about this real-world question. Biographies: Todd Matthew Morgan MD Associate Professor Specialties: Urology Area of Practice: Prostate Cancer, including robotic prostatectomy and active surveillance; Bladder Cancer, inclu...
|
- Details
- Daniel Spratt, MD, and Todd Morgan, MD discuss the role of social media in medical and scientific communication with Charles Ryan, MD. All three agree that social media, especially Twitter, helps to provide quicker access to breaking information at congresses when it is not possible to attend the live meeting. This communication outlet also typically provides more expert opinion and commentary tha...
|
- Details
- FGFR alterations and specifically ones involving the third and the second isotype of the receptor, FGFR3 and FGFR2, are activated and present in between 15 to 20%, possibly higher, of patients with locally advanced and metastatic bladder cancer. We know that these are genetic drivers and the therapeutic targeting of this pathway can lead to responses. Patients should be selected for therapy based...
|
- Details
- Art Rastinehad provides insight into the role of focal therapy in the treatment of prostate cancer. He begins the presentation with the evolution of prostate cancer care. He describes focal therapy in the context of the next significant opportunity in the treatment of prostate cancer once we have a positive biopsy and walks us through the why, the who the how and the where in defining focal therap...
|
- Details
- Phillip Koo, MD hosts a lecture in the core curriculum which is developed by the Prostate Cancer Outreach Working Group of the SNMMI. The Prostate Cancer Working Group focuses on increasing awareness of oncologists, urologists and family practitioners about imaging and therapy technologies such as FACBC, bone scintigraphy, and radium-223. This lecture series will cover the complete spectrum of pro...
|
- Details
- Alicia Morgans and Adam Kibel discuss the evolving landscape of urologic oncology, specifically focusing on prostate cancer. Dr. Kibel expresses his interest in using genetics, such as single nucleotide polymorphisms, for early identification of high-risk patients and predicting the risk of aggressive prostate cancer. This approach may influence future screening strategies and prophylactic interve...
|
- Details
- Alicia Morgans invites Claire Pernar to highlight her efforts on the topic of cognitive function in men with prostate cancer. Cognitive impairment is a key component of wellbeing in men with prostate cancer, and it can affect men's thinking, their language, and their memory. This is an area many seek to understand and to identify any unmet needs. Claire's work is being facilitated in the context o...
|
- Details
- Tian Zhang and Alicia Morgans discuss the three new approvals for the first line treatment of metastatic renal cell carcinoma, including cabozantinib with targeted agents, IO combinations with ipilimumab and nivolumab and now the recent approval of pembrolizumab plus axitinib. Dr. Zhang reviews the long-term follow-up from the CHECKMATE-214 study along with the CABOSUN data. The discussion conclud...
|
- Details
- Oliver Sartor, MD discusses his contributions to the recent publication in JAMA Oncology on the prevalence of germline variants in prostate cancer and the implications for genetic testing guidelines. 3600 patients had various forms of germiline genetic testing performed and were available for this analysis. In the dataset, 17% of patients had germline variants and 30% of those were BRCA1/BRCA2. In...
|
- Details
- Anis Hamid and Chris Sweeney discuss their recent work studying biomarkers across the full spectrum of prostate cancer. Based on preclinical studies we understand that aggressive disease lies in the tumor genome and we see recurrent losses of certain genes in both early and advanced prostate cancer. The classic tumor suppressors that are commonly mutated across cancers, including prostate cancer,...
|
